Diabetic Neuropathy

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 4, 2013, Pages 747-787

  Vinik, Aaron I ^a   Nevoret, Marie Laure ^a   Casellini, Carolina ^a   Parson, Henri ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Painful neuropathy; Pregabalin

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BOTULINUM TOXIN; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FELBAMATE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; NORTRIPTYLINE; OXCARBAZEPINE; OXYCODONE; PAROXETINE; PLACEBO; PREGABALIN; TAPENTADOL; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE;

ANOREXIA; ATAXIA; AUTONOMIC NEUROPATHY; BEDTIME DOSAGE; BLURRED VISION; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CHRONIC SENSORIMOTOR NEUROPATHY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; CONFUSION; CONSTIPATION; DEMYELINATING NEUROPATHY; DIABETES MELLITUS; DIABETIC CARDIAC AUTONOMIC NEUROPATHY; DIABETIC NEUROPATHY; DIABETIC TRUNCAL RADICULONEUROPATHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MEGADOSE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERGLYCEMIC NEUROPATHY; IMMUNOTHERAPY; IMPOTENCE; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; METABOLIC REGULATION; MONONEUROPATHY; MORBIDITY; MORTALITY; MUSCLE ATROPHY; NAUSEA; NEUROLOGIC EXAMINATION; NEUROMA; NEUROPATHIC JOINT DISEASE; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTIVE PAIN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PAIN ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENSORY ANALYSIS; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; TACHYCARDIA; TREMOR; TRIGEMINUS NEURALGIA; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; PAINFUL NEUROPATHY; PREGABALIN;

AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOVASCULAR DISEASES; DIABETIC NEUROPATHIES; GUIDELINES AS TOPIC; HUMANS; HYPERGLYCEMIA; NEURALGIA;

EID: 84888088112     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.06.001     Document Type: Review

References (186)

1. Vinik A.I., Mitchell B.D., Leichter S.B., et al. Epidemiology of the complications of diabetes. Diabetes: clinical science in practice 1995, 221-287. Cambridge University Press, Cambridge (United Kingdom). R.D. Leslie, D.C. Robbins (Eds.).
2. Holzer S.E., Camerota A., Martens L., et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998, 20:169-181.
3. Caputo G.M., Cavanagh P.R., Ulbrecht J.S., et al. Assessment and management of foot disease in patients with diabetes. NEngl J Med 1994, 331:854-860.
4. Herman W.H., Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005, 28:1480-1481.
5. Young M.J., Boulton A.J., MacLeod A.F., et al. Amulticenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150-154.
6. Dyck P.J., Kratz K.M., Karnes J.L., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817-824.
7. Vinik A. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999, 107(2B):17S-26S.
8. Armstrong D.G., Lavery L.A., Harkless L.B. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21:855-859.
9. Vinik E.J., Hayes R.P., Oglesby A., et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005, 7:497-508.
10. Levitt N.S., Stansberry K.B., Wychanck S., et al. Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM. Diabetes Care 1996, 19:751-754.
11. Rathmann W., Ziegler D., Jahnke M., et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993, 10:820-824.
12. Vinik A., Ullal J., Parson H.K., et al. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006, 2:269-281.
13. Sadosky A., McDermott A.M., Brandenburg N.A., et al. Areview of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008, 8:45-56.
14. Tesfaye S., Boulton A.J., Dyck P.J., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293.
15. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008, 24(Suppl 1):S52-S57.
16. Boulton A.J., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
17. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115:387-397.
18. Vinik A.I., Maser R.E., Ziegler D. Neuropathy: the crystal ball for cardiovascular disease?. Diabetes Care 2010, 33:1688-1690.
19. Vinik A.I., Maser R.E., Ziegler D. Autonomic imbalance: prophet of doom or scope for hope?. Diabet Med 2011, 28:643-651.
20. Dieleman J.P., Kerklaan J., Huygen F.J., et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008, 137:681-688.
21. Cornblath D.R., Vinik A., Feldman E., et al. Surgical decompression for diabetic sensorimotor polyneuropathy. Diabetes Care 2007, 30:421-422.
22. Ziegler D., Rathmann W., Dickhaus T., et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008, 31:464-469.
23. Smith A.G., Russell J., Feldman E.L., et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006, 29:1294-1299.
24. Ziegler D., Rathmann W., Meisinger C., et al. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009, 13:582-587.
25. Ziegler D., Rathmann W., Dickhaus T., et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009, 10:393-400.
26. Vinik A.I., Holland M.T., LeBeau J.M., et al. Diabetic neuropathies. Diabetes Care 1992, 15:1926-1975.
27. Vinik A., Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004, 88:947-999.
28. Vinik A., Mehrabyan A., Colen L., et al. Focal entrapment neuropathies in diabetes. Diabetes Care 2004, 27:1783-1788.
29. Wilbourn A.J. Diabetic entrapment and compression neuropathies. Diabetic neuropathy 1999, 481-508. WB Saunders, Toronto. P.J. Dyck, P.K. Thomas (Eds.).
30. Watanabe K., Hagura R., Akanuma Y., et al. Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract 1990, 10:19-27.
31. Perkins B., Olaleye D., Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002, 25:565-569.
32. Llewelyn J.G., Thomas P.K., King R.H. Epineurial microvasculitis in proximal diabetic neuropathy. JNeurol 1998, 245:159-165.
33. Vinik A.I., Pittenger G.L., Milicevic Z., et al. Autoimmune mechanisms in the pathogenesis of diabetic neuropathy. Molecular mechanisms of endocrine and organ specific autoimmunity 1998, 217-251. Landes Company, Georgetown, Texas. 1st edition. R.G. Eisenbarth (Ed.).
34. Steck A.J., Kappos L. Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies. JNeurol Neurosurg Psychiatry 1994, 57(Suppl):26-28.
35. Ayyar D.R., Sharma K.R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus. Curr Diab Rep 2004, 4:409-412.
36. Krendel D.A., Costigan D.A., Hopkins L.C. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995, 52:1053-1061.
37. Barada A., Reljanovic M., Milicevic Z., et al. Proximal diabetic neuropathy-response to immunotherapy. Diabetes 1999, 48(Suppl 1):A148.
38. Boulton A.J., Malik R.A. Diabetic neuropathy. Med Clin North Am 1998, 82:909-929.
39. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997, 46(Suppl 2):S54-S57.
40. Oyibo S.O., Prasad Y.D., Jackson N.J., et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002, 19:870-873.
41. Sinnreich M., Taylor B.V., Dyck P.J. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist 2005, 11:63-79.
42. Vinik A. Management of the patient with neuropathic pain 2012, 177-194. Endocrine Society, J Clin Endocrinol Metab 2010;95:4802-11 [reprint]. L. Wartofsky (Ed.).
43. Archer A.G., Watkins P.J., Thomas P.K., et al. The natural history of acute painful neuropathy in diabetes mellitus. JNeurol Neurosurg Psychiatry 1983, 46:491-499.
44. Partanen J., Niskanen L., Lehtinen J., et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. NEngl J Med 1995, 333:89-94.
45. Harris M., Eastman R., Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993, 16:1446-1452.
46. Singleton J.R., Smith A.G., Bromberg M.B. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001, 24:1225-1228.
47. Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448-1453.
48. Novella S.P., Inzucchi S.E., Goldstein J.M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001, 24:1229-1231.
49. Sumner C., Sheth S., Griffin J., et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108-111.
50. Pittenger G.L., Ray M., Burcus N.I., et al. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 2004, 27:1974-1979.
51. Dyck P.J., Lais A., Karnes J.L., et al. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986, 19:425-439.
52. Cavanagh P.R., Simoneau G.G., Ulbrecht J.S. Ulceration, unsteadiness, and uncertainty: the biomechanical consequences of diabetes mellitus. JBiomech 1993, 26(Suppl 1):23-40.
53. Katoulis E.C., Ebdon-Parry M., Lanshammar H., et al. Gait abnormalities in diabetic neuropathy. Diabetes Care 1997, 20:1904-1907.
54. Vinik A.I., Strotmeyer E.S., Nakave A.A., et al. Diabetic neuropathy in older adults. Clin Geriatr Med 2008, 24:407-435.
55. England J.D., Gronseth G.S., Franklin G., et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005, 64:199-207.
56. Ziegler D., Hidvegi T., Gurieva I., et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010, 33:839-841.
57. Young R.J., Ewing D.J., Clarke B.F. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988, 11:34-40.
58. England J.D., Gronseth G.S., Franklin G., et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72:177-184.
59. Feldman E.L., Stevens M.J., Thomas P.K., et al. Apractical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994, 17:1281-1289.
60. Haanpaa M.L., Backonja M.M., Bennett M.I., et al. Assessment of neuropathic pain in primary care. Am J Med 2009, 122:S13-S21.
61. Boulton A.J., Vinik A.I., Arezzo J.C., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
62. Boulton A.J., Gries F.A., Jervell J.A. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabet Med 1998, 15:508-514.
63. Vinik A.I., Suwanwalaikorn S., Stansberry K.B., et al. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995, 18:574-584.
64. Abbott C.A., Carrington A.L., Ashe H., et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002, 19:377-384.
65. Dyck P.J., Melton L.J., O'Brien P.C., et al. Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study. Diabetes 1997, 46(Suppl 2):S5-S8.
66. Vileikyte L., Peyrot M., Bundy C., et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003, 26:2549-2555.
67. Cameron N.E., Eaton S.E., Cotter M.A. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973-1988.
68. Albers J.W., Herman W.H., Pop-Busui R., et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010, 33:1090-1096.
69. Pop-Busui R., Low P.A., Waberski B.H., et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886-2893.
70. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
71. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358:2560-2572.
72. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. NEngl J Med 2008, 358:580-591.
73. Ziegler D., Sohr C.G., Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004, 27:2178-2183.
74. Pittenger G., Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003, 4:271-285.
75. Vinik A.I. Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve growth factor (rhNGF). Diabetes 1999, 48(Suppl 1):A54-A55.
76. Rivard A., Silver M., Chen D., et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999, 154:355-363.
77. Tam J., Rosenberg L., Maysinger D. INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. FASEB J 2004, 18:1767-1769.
78. Dungan K.M., Buse J.B., Ratner R.E. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev 2009, 25:558-565.
79. Bussolino F., Di Renzo M.F., Ziche M., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. JCell Biol 1992, 119:629-641.
80. Nakagami H., Kaneda Y., Ogihara T., et al. Hepatocyte growth factor as potential cardiovascular therapy. Expert Rev Cardiovasc Ther 2005, 3:513-519.
81. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. JBiochem 1996, 119:591-600.
82. Jayasankar V., Woo Y.J., Pirolli T.J., et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. JCard Surg 2005, 20:93-101.
83. Hashimoto N., Yamanaka H., Fukuoka T., et al. Expression of HGF and cMet in the peripheral nervous system of adult rats following sciatic nerve injury. Neuroreport 2001, 12:1403-1407.
84. Ajroud-Driss S., Christiansen M., Allen J.A., et al. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther 2013, 21(6):1279-1286.
85. Milicevic Z., Newlon P.G., Pittenger G.L., et al. Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features. Diabetologia 1997, 40:1364-1365.
86. Sharma K., Cross J., Farronay O., et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758-765.
87. Granberg V., Ejskjaer N., Peakman M., et al. Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005, 28:1959-1964.
88. Vinik A.I., Anandacoomaraswamy D., Ullal J. Antibodies to neuronal structures: innocent bystanders or neurotoxins?. Diabetes Care 2005, 28:2067-2072.
89. Mantyselka P., Ahonen R., Kumpusalo E., et al. Variability in prescribing for musculoskeletal pain in Finnish primary health care. Pharm World Sci 2001, 23:232-236.
90. Treede R.D., Jensen T.S., Campbell J.N., et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008, 70:1630-1635.
91. Jensen M.P., Chodroff M.J., Dworkin R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007, 68:1178-1182.
92. Bouhassira D., Lanteri-Minet M., Attal N., et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008, 136:380-387.
93. Vinik E., Paulson J., Ford-Molvik S., et al. German-Translated Norfolk Quality of Life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. JDiabetes Sci Technol 2008, 2:1075-1086.
94. Vinik A.I., Casellini C.M. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes Metab Syndr Obes 2013, 6:57-78.
95. Vinik A., Emir B., Raymond C., et al. The relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or post-herpetic neuralgia treated with pregabalin. Clin Ther 2013, 35(5):612-623.
96. Castro M.M., Daltro C. Sleep patterns and symptoms of anxiety and depression in patients with chronic pain. Arq Neuropsiquiatr 2009, 67:25-28.
97. Gore M., Brandenburg N.A., Dukes E., et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. JPain Symptom Manage 2005, 30:374-385.
98. Boulanger L., Zhao Y., Foster T.S., et al. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin 2009, 25:1763-1773.
99. Gupta A., Silman J., Ray D., et al. The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology 2007, 46:666-671.
100. O'Connor A.B. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009, 27:95-112.
101. Daousi C., MacFarlane I.A., Woodward A., et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004, 21:976-982.
102. Bennett M.I., Attal N., Backonja M.M., et al. Using screening tools to identify neuropathic pain. Pain 2007, 127:199-203.
103. Bastyr E., Zhang D., Bril V., The MBBQ Study Group Neuropathy Total symptom Score-6 Questionnaire (NTSS-6) is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN). Diabetes 2002, 51:A199.
104. Scholz J., Mannion R.J., Hord D.E., et al. Anovel tool for the assessment of pain: validation in low back pain. PLoS Med 2009, 6:e1000047.
105. Spallone V, Morganti R, D'Amato C, et al. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. Eur J Pain 2011, 15(2):153-160.
106. Young R.J. Structural functional interactions in the natural history of diabetic polyneuropathy: a key to the understanding of neuropathic pain?. Diabet Med 1993, 10(Suppl 2):89S-90S.
107. Loeser J.D., Treede R.D. The Kyoto protocol of IASP basic pain terminology. Pain 2008, 137:473-477.
108. Bouhassira D., Attal N., Fermanian J., et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004, 108:248-257.
109. Bennett M.I., Smith B.H., Torrance N., et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. JPain 2005, 6:149-158.
110. Krause S., Backonja M. Development of a neuropathic pain questionnaire. Clin J Pain 2003, 19:306-314.
111. Bouhassira D., Attal N., Alchaar H., et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005, 114:29-36.
112. Freyhagen R., Baron R., Gockel U. Pain detect: a new screening questionnaire to detect neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22:1911-1920.
113. Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID pain. Curr Med Res Opin 2006, 22:1555-1565.
114. Dworkin R.H., Turk D.C., Revicki D.A., et al. Development and initial validation of anexpanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009, 144:35-42.
115. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983, 17:197-210.
116. Dworkin R.H., Turk D.C., Wyrwich K.W., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. JPain 2008, 9:105-121.
117. Cruccu G., Truini A. Tools for assessing neuropathic pain. PLoS Med 2009, 6:e1000045.
118. Stephenson D.T., Arneric S.P. Neuroimaging of pain: advances and future prospects. JPain 2008, 9:567-579.
119. Chao C.C., Hsieh S.C., Tseng M.T., et al. Patterns of contact heat evoked potentials (CHEP) in neuropathy with skin denervation: correlation of CHEP amplitude with intraepidermal nerve fiber density. Clin Neurophysiol 2008, 119:653-661.
120. Atherton D.D., Facer P., Roberts K.M., et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol 2007, 7:21.
121. Casanova-Molla J., Grau-Junyent J.M., Morales M., et al. On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain 2011, 152:410-418.
122. Chao C.C., Tseng M.T., Lin Y.J., et al. Pathophysiology of neuropathic pain in type 2 diabetes: skin denervation and contact heat-evoked potentials. Diabetes Care 2010, 33:2654-2659.
123. Finnerup N.B., Otto M., McQuay H.J., et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118:289-305.
124. Finnerup N.B., Sindrup S.H., Jensen T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-581.
125. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
126. Dworkin R.H., O'Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85:S3-S14.
127. Edelsberg J., Oster G. Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?. Eur J Pain 2009, 13:11-16.
128. Said G., Bigo A., Ameri A., et al. Uncommon early-onset neuropathy in diabetic patients. JNeurol 1998, 245:61-68.
129. Dogrul A., Uzbay I.T. Topical clonidine antinociception. Pain 2004, 111:385-391.
130. Tesfaye S., Vileikyte L., Rayman G., et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011, 27:629-638.
131. Bril V., England J., Franklin G.M., et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011, 76:1758-1765.
132. Vinik A. The approach to the management of the patient with neuropathic pain. JClin Endocrinol Metab 2010, 95:4802-4811.
133. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004, 21:114-121.
134. Ziegler D., Low P.A., Boulton A.J. Antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: a 4-year randomized double-blind trial (NATHAN 1). Diabetologia 2011, 50:S63.
135. Rains C., Bryson H.M. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995, 7:317-328.
136. Mason L., Moore R.A., Derry S., et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004, 328:991.
137. Backonja M., Wallace M.S., Blonsky E.R., et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008, 7:1106-1112.
138. Baron R., Mayoral V., Leijon G., et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009, 25:1677-1687.
139. Jarvis B., Coukell A.J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998, 56:691-707.
140. Harati Y., Gooch C., Swenson M., et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
141. Harati Y., Gooch C., Swenson M., et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. JDiabetes Complications 2000, 14:65-70.
142. Nelson K.A., Park K.M., Robinovitz E., et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997, 48:1212-1218.
143. Sang C.N. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. JPain Symptom Manage 2000, 19:S21-S25.
144. Watson C.P., Moulin D., Watt-Watson J., et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
145. Gilron I., Bailey J.M., Tu D., et al. Morphine, gabapentin, or their combination for neuropathic pain. NEngl J Med 2005, 352:1324-1334.
146. Max M., Lynch S., Muir J. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. NEngl J Med 1992, 326:1250-1256.
147. Hardy T., Sachson R., Shen S., et al. Does treatment with duloxetine for neuropathic pain impact glycemic control?. Diabetes Care 2007, 30:21-26.
148. Sansone R.A., Sansone L.A. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont) 2008, 5:16-19.
149. Simpson D.A. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. JClin Neuromuscul Dis 2001, 3:53-62.
150. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (g-32883). Lancet 1962, 21:839-840.
151. LaRoche S.M., Helmers S.L. The new antiepileptic drugs: scientific review. JAMA 2004, 291:605-614.
152. Dworkin R.H., Backonja M., Rowbotham M.C., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003, 60:1524-1534.
153. Landefeld C.S., Steinman M.A. The Neurontin legacy-marketing through misinformation and manipulation. NEngl J Med 2009, 360:103-106.
154. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836.
155. DeToledo J.C., Toledo C., DeCerce J., et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997, 19:394-396.
156. Lesser H., Sharma U., LaMoreaux L., et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104-2110.
157. Richter R.W., Portenoy R., Sharma U., et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. JPain 2005, 6:253-260.
158. Rosenstock J., Tuchman M., LaMoreaux L., et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638.
159. Freynhagen R., Strojek K., Griesing T., et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115:254-263.
160. Freeman R., Durso-Decruz E., Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008, 31:1448-1454.
161. Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des 2005, 11:3005-3011.
162. Dogra S., Beydoun S., Mazzola J., et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005, 9:543-554.
163. Vinik A.I. Diabetic neuropathies: endpoints in clinical research studies. Contemporary endocrinology: controversies in treating diabetes: clinical and research aspects 2008, 135-156. Humana Press, Totowa (NJ). D. LeRoith, A.I. Vinik (Eds.).
164. Pittenger G., Mehrabyan A., Simmons K., et al. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord 2005, 3:113-121.
165. Raskin P., Donofrio P.D., Rosenthal N.R., et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004, 63:865-873.
166. Quilici S., Chancellor J., Lothgren M., et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009, 9:6-19.
167. Burke J., Sanchez R., Joshi A., et al. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract 2012, 12:209-218.
168. De Salas-Cansado M., Perez C., Saldana M.T., et al. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes 2012, 6:303-312.
169. Bellows B.K., Dahal A., Jiao T., et al. Acost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. JPain Palliat Care Pharmacother 2012, 26:153-164.
170. Gilron I., Bailey J.M., Tu D., et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009, 374:1252-1261.
171. Thethi T.K., Fonseca V.A., Lavery L.A., et al. Metanx in Type 2 Diabetes with Peripheral Neuropathy, A Randomized Trial. Am J Med 2013, 126(2):141-149.
172. Vinik A.J. A medicinal food provides food for thought in managing diabetic neuropathy. Am J Med 2013, 126(2):95-96.
173. Piovesan E.J., Teive H.G., Kowacs P.A., et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005, 65:1306-1308.
174. Tsai C.P., Liu C.Y., Lin K.P., et al. Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome: a preliminary experience. Clin Drug Investig 2006, 26:511-515.
175. Pittler M.H., Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008, 24:731-733.
176. Tesfaye S. Painful diabetic neuropathy. Aetiology and nonpharmacological treatment. Clinical management of diabetic neuropathy 1998, 369-386. Humana Press, Totowa (NJ). A. Veves (Ed.).
177. Spallone V., Ziegler D., Freeman R., et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011, 27:639-653.
178. Maser R.E., Mitchell B.D., Vinik A.I., et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003, 26:1895-1901.
179. Ziegler D., Zentai C.P., Perz S., et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008, 31:556-561.
180. Lykke J.A., Tarnow L., Parving H.H., et al. Acombined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008, 68:654-659.
181. Hage F.G., Iskandrian A.E. Cardiovascular imaging in diabetes mellitus. JNucl Cardiol 2011, 18:959-965.
182. Burgos L.G., Ebert T.J., Assiddao C., et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989, 70:591-597.
183. Kitamura A., Hoshino T., Kon T., et al. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 2000, 92:1311-1318.
184. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. JAuton Nerv Syst 1996, 58:123-124.
185. Low P.A., Walsh J.C., Huang C.Y., et al. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. Brain 1975, 98:341-356.
186. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999, 353:617-622.